by Clare Gerrard | Mar 26, 2025
Neuroendocrine Cancer UK are delighted that our article. ‘Are NENs no longer a rare cancer?’ has been published in the March edition of Neuroendocrinology. For the patient community, this article is a powerful step forward. It highlights the need for better...
by Clare Gerrard | Aug 13, 2024
Healthcare Professional Webinars: PERT and what to do during current shortages (Please note: that these webinars are specifically for healthcare professionals: including hospital clinicians/prescribers, GPs, CNSs & both hospital and community pharmacists) Many of...
by Clare Gerrard | Jul 10, 2023
Neuroendocrine Cancer UK Announces Partnership with RareCan to help Facilitate Access to Clinical Trial Opportunities Neuroendocrine Cancer UK is excited to announce a partnership with RareCan to help grow cohorts of people with neuroendocrine cancer, empowering them...
by Clare Gerrard | May 9, 2023
Neuroendocrine cancers (NC) are England’s tenth most prevalent cancer. Yet awareness of these cancers is very low, even among healthcare professionals (HCPs). People living with NC experience inequities in diagnosis, disease management and care due to a lack of...
by Leanne Talbot | Mar 29, 2021
Ovarian Neuroendocrine Cancer – The Facts The incidence of temporary amenorrhoea or early menopause due to cancer or its treatments varies according to the age, pubertal status, existing ovarian reserve and type of cancer and/or treatment. The risk of menopause...
